Table 3.
Univariate and multivariate Cox proportional hazard regression evaluating the risk of endpoint (death or heart transplantation) in the entire cohort
| Univariate | Multivariate | ||||||
|---|---|---|---|---|---|---|---|
| p | Model 1 N patients = 72 N events = 23 |
Model 2 N patients = 71 N events = 23 |
Model 3 N patients = 65 N events = 20 |
||||
| HR [CI] | P | HR [CI] | P | HR [CI] | P | ||
| Baseline characteristics | |||||||
| Age (years) | 0.564 | ||||||
| Male gender | 0.004 | 3.11 [1.20–8.05] | 0.019 | 4.11 [1.65–10.23] | 0.002 | 2.84 [0.98–8.26] | 0.055 |
| BMI (kg/m2) | 0.151 | ||||||
| GCM diagnosis | < 0.001 | 3.61 [1.42–9.21] | 0.007 | 3.47 [1.37–8.79] | 0.009 | 2.69 [0.81–8.94] | 0.106 |
| NT-proBNP (pg/L) | < 0.001 | 1.00 [1.00–1.00] | 0.259 | ||||
| eGFR (ml/min/1.73 m2) | 0.008 | ||||||
| NYHA class ≥ III | < 0.001 | 3.38 [1.13–10.12] | 0.03 | ||||
| Prevalent clinical cardiac manifestations | |||||||
| Heart failure | 0.094 | ||||||
| Sustained VT or cardiac arrest | 0.576 | ||||||
| High-grade AVB | 0.06 | ||||||
| Echocardiography findings | |||||||
| LV EF (%) | < 0.001 | 0.95 [0.91–0.99] | 0.01 | ||||
| RV dyfunction | 0.005 | 1.29 [0.47–3.56] | 0.627 | 1.67 [0.64–4.35] | 0.293 | 2.39 [0.82–7.05] | 0.06 |
AVB, atrio-ventricular block; BMI, body mass index; CI, confidence interval; eGFR, estimated glomerular filtration rate; GCM, giant cell myocarditis; HR, hazard ratio; LV EF, left ventricle ejection fraction; NYHA, New York Heart Association; NT-proBNP, N-terminal pro-B-type; RV, right ventricular; VT, ventricular tachycardia